Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients

EJNMMI Research

Table 3 Univariate and multivariate cox proportional hazards regression for PFS

	Variables	Univariate analysis			Multivariate analysis
	Variables	p value	HR	95% CI	p value	HR	95% CI
Clinical characteristics	COO subtypes Age Gender Ann Arbor stage IPI LDH β2-MG Ferritin	0.458 0.112 0.559 0.004 0.006 0.843 0.060 0.782	0.776 1.020 1.806 3.070 2.460 1.000 1.043 1.000	0.398–1.516 0.995–1.045 0.394–3.493 1.430–6.593 1.292–4.683 1.000–1.000 0.998–1.090 1.000–1.000
Semi-quantitative parameters	ΔSUVmax_(LLR)¹ ΔTMTV¹ ΔTLG¹	0.000* 0.000* 0.000***	1.030 1.032 1.039	1.021–1.039 1.015–1.048 1.023–1.056	0.000* 0.004 0.008**	1.024 1.026 1.030	1.013–1.035 1.008–1.044 1.008–1.053
	ΔSUVmax_(LLR)²	0.000***	1.007	1.003–1.011
	ΔTMTV²	0.525	1.000	0.999–1.001
	ΔTLG²	0.675	1.000	1.000–1.000
I-VA	CMR or non-CMR	0.000***	4.163	2.184–7.936
E-VA	CMR or non-CMR	0.000***	10.876	3.765–31.495

^***p < 0.001, **p < 0.01, *p < 0.05
PFS progression-free survival, HR Hazard Ratio, CI confidence interval, COO cell of origin, IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-Microglobulin, SUVmax maximum standardized uptake value, LLR lesion-to-liver ratio calculated as SUVmax of the residual divided by SUVmax of the liver, TMTV total metabolic tumor volume, TLG total lesion glycolysis, VA visual analysis, CMR complete metabolic response, I interim, E end of treatment, 1 interim compared to baseline, 2 end of treatment compared to baseline